Adaptive Biotechnologies Corp.

About Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp. is a pioneering biotechnology company that focuses on harnessing the power of the immune system to transform the diagnosis and treatment of diseases. Founded in 2009, the company has developed innovative technologies that enable the analysis of T-cell receptors and B-cell receptors, which are crucial for understanding immune responses.

With a commitment to advancing precision medicine, Adaptive Biotechnologies aims to provide insights into the immune repertoire, facilitating the development of targeted therapies and diagnostics. The company’s flagship product, the clonoSEQ assay, is the first FDA-approved test for monitoring minimal residual disease in blood cancers, showcasing its dedication to improving patient outcomes.

Adaptive’s research extends beyond oncology, exploring applications in autoimmune diseases, infectious diseases, and organ transplantation. By leveraging advanced sequencing technologies and machine learning, the company is at the forefront of immunology research, driving breakthroughs that can lead to more effective treatments.

The company operates with a vision to empower clinicians and patients with actionable insights derived from the immune system. Through collaborations with leading academic institutions and pharmaceutical companies, Adaptive Biotechnologies is expanding its reach and impact in the healthcare landscape.

Headquartered in Seattle, Washington, Adaptive Biotechnologies is committed to fostering a culture of innovation and excellence. The company employs a diverse team of scientists, engineers, and healthcare professionals who share a passion for improving human health.

As Adaptive Biotechnologies continues to grow, it remains focused on its mission to unlock the potential of the immune system, ultimately aiming to change the way diseases are diagnosed and treated worldwide.